Immuno-oncology

The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.

Pharmacists have an important role in helping patients to identify treatment-related toxicities and manage symptoms to help the transition to the outpatient setting.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

Among patients with lung cancer, approximately 20% have the earliest stage of disease but are still dying of metastatic lung cancer within about 5 years.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

CRISPR technology has also been successful in treating a pediatric patient with T-cell acute lymphoblastic leukemia, showing feasibility of its use for cancer immunotherapy.

Cancer Moonshot Initiative launched efforts to investigate how to better support patients with cancer by providing support in the navigation of the diagnosis, treatment, and survival of cancer.

Ventana PD-L1 (SP263) Assay can increase access to cemiplimab and improve patient outcomes in non-small cell lung cancer.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.

Therapy consists of high-dose abatacept, ruxolitinib, and proactive monitoring for respiratory muscle involvement.

Idecabtagene vicleucel prolonged progression-free survival by more than 1 year in a difficult-to-treat patient population with relapsed or refractory multiple myeloma.

Investigators hope that new findings can cultivate new methods of facilitating immune response to attack lung tumors.

Approval of a novel antibody-drug conjugate ushers in new second-line option.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Pipeline includes more than 100 products encompassing bone health, cancer care, immunosuppressants, ophthalmology.

CAR T cell gel eliminated the residual tumor cells in almost all mouse models, allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.

A retrospective analysis presents unique results for AML treatment.

The head of the CAR T cell antibody can recognize and target the growth factor in its tumor microenvironment.

Viral infections can plague patients who have undergone stem cell transplantation.

Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

The dual-action cell therapy is designed to eliminate established tumors, train the immune system to eradicate a primary tumor, and prevent recurrence.